Molecular Assemblies Closes Oversubscribed $24 Million Series A Financing to Advance Enzymatic DNA Synthesis toward Initial Commercial Access News provided by Share this article Share this article SAN DIEGO, April 15, 2021 /PRNewswire/ -- Molecular Assemblies, Inc., today announced that it has closed an oversubscribed $24 million Series A financing with significant investment from Agilent Technologies, iSelect Fund, Codexis, Alexandria Venture Investments, and Argonautic Ventures. In addition LYFE Capital has joined the syndicate. The proceeds of the financing will be used to advance the company's proprietary enzymatic DNA synthesis technology toward early commercialization efforts. "We have made significant progress in advancing our proprietary enzymatic DNA synthesis technology," said Michael J. Kamdar, President and CEO of Molecular Assemblies. "Over the past year, we've entered into a transformative partnership with Codexis and joined a new project with GE Research to enable the production of nucleic acid-based vaccines and therapeutics, anywhere in the world. We are delighted to have closed our Series A and are rapidly advancing our efforts towards early commercial access."